BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Van Biervliet S, Vanbillemont G, Van Biervliet J, Declercq D, Robberecht E, Christophe A. Relation between Fatty Acid Composition and Clinical Status or Genotype in Cystic Fibrosis Patients. Ann Nutr Metab 2008;51:541-9. [DOI: 10.1159/000114208] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 2.1] [Reference Citation Analysis]
Number Citing Articles
1 Mimoun M, Coste TC, Lebacq J, Lebecque P, Wallemacq P, Leal T, Armand M. Increased Tissue Arachidonic Acid and Reduced Linoleic Acid in a Mouse Model of Cystic Fibrosis Are Reversed by Supplemental Glycerophospholipids Enriched in Docosahexaenoic Acid. The Journal of Nutrition 2009;139:2358-64. [DOI: 10.3945/jn.109.110999] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 1.6] [Reference Citation Analysis]
2 Aldámiz-echevarría L, Prieto JA, Andrade F, Elorz J, Sojo A, Lage S, Sanjurjo P, Vázquez C, Rodríguez-soriano J. Persistence of Essential Fatty Acid Deficiency in Cystic Fibrosis Despite Nutritional Therapy. Pediatr Res 2009;66:585-9. [DOI: 10.1203/pdr.0b013e3181b4e8d3] [Cited by in Crossref: 42] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
3 Umunakwe OC, Seegmiller AC. Abnormal n-6 fatty acid metabolism in cystic fibrosis is caused by activation of AMP-activated protein kinase. J Lipid Res 2014;55:1489-97. [PMID: 24859760 DOI: 10.1194/jlr.M050369] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
4 Wheelock CE, Strandvik B. Abnormal n-6 fatty acid metabolism in cystic fibrosis contributes to pulmonary symptoms. Prostaglandins Leukot Essent Fatty Acids 2020;160:102156. [PMID: 32750662 DOI: 10.1016/j.plefa.2020.102156] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
5 Thomsen KF, Laposata M, Njoroge SW, Umunakwe OC, Katrangi W, Seegmiller AC. Increased elongase 6 and Δ9-desaturase activity are associated with n-7 and n-9 fatty acid changes in cystic fibrosis. Lipids 2011;46:669-77. [PMID: 21544602 DOI: 10.1007/s11745-011-3563-z] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
6 Tournoud M, Ecochard R, Iwaz J, Steghens J, Bellon G, Durieu I. Structural equations to model relationships between pulmonary function, fatty acids and oxidation in cystic fibrosis. Scandinavian Journal of Clinical and Laboratory Investigation 2009;69:36-44. [DOI: 10.1080/00365510802287265] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
7 Hanssens L, Duchateau J, Namane S, Malfroot A, Knoop C, Casimir G. Influence of lung transplantation on the essential fatty acid profile in cystic fibrosis. Prostaglandins, Leukotrienes and Essential Fatty Acids 2020;158:102060. [DOI: 10.1016/j.plefa.2020.102060] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Tiesset H, Bernard H, Bartke N, Beermann C, Flachaire E, Desseyn J, Gottrand F, Husson M. (n-3) Long-Chain PUFA Differentially Affect Resistance to Pseudomonas aeruginosa Infection of Male and Female cftr–/– Mice. The Journal of Nutrition 2011;141:1101-7. [DOI: 10.3945/jn.110.134585] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
9 Strandvik B, O Neal WK, Ali MA, Hammar U. Low linoleic and high docosahexaenoic acids in a severe phenotype of transgenic cystic fibrosis mice. Exp Biol Med (Maywood) 2018;243:496-503. [PMID: 29513100 DOI: 10.1177/1535370218758605] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
10 Galli F, Battistoni A, Gambari R, Pompella A, Bragonzi A, Pilolli F, Iuliano L, Piroddi M, Dechecchi MC, Cabrini G. Oxidative stress and antioxidant therapy in cystic fibrosis. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 2012;1822:690-713. [DOI: 10.1016/j.bbadis.2011.12.012] [Cited by in Crossref: 124] [Cited by in F6Publishing: 117] [Article Influence: 12.4] [Reference Citation Analysis]
11 Hanssens L, Thiébaut I, Lefèvre N, Malfroot A, Knoop C, Duchateau J, Casimir G. The clinical benefits of long-term supplementation with omega-3 fatty acids in cystic fibrosis patients - A pilot study. Prostaglandins Leukot Essent Fatty Acids 2016;108:45-50. [PMID: 27154364 DOI: 10.1016/j.plefa.2016.03.014] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 2.7] [Reference Citation Analysis]
12 Van Biervliet S, Van Biervliet JP, Robberecht E, Christophe A. Fatty acid composition of serum phospholipids in cystic fibrosis (CF) patients with or without CF related liver disease. Clin Chem Lab Med. 2010;48:1751-1755. [PMID: 20961201 DOI: 10.1515/cclm.2010.336] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
13 Hamazaki T, Suzuki N, Widyowati R, Miyahara T, Kadota S, Ochiai H, Hamazaki K. The depressive effects of 5,8,11-eicosatrienoic Acid (20:3n-9) on osteoblasts. Lipids 2009;44:97-102. [PMID: 18941818 DOI: 10.1007/s11745-008-3252-8] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
14 Causer AJ, Shute JK, Cummings MH, Shepherd AI, Gruet M, Costello JT, Bailey S, Lindley M, Pearson C, Connett G, Allenby MI, Carroll MP, Daniels T, Saynor ZL. Circulating biomarkers of antioxidant status and oxidative stress in people with cystic fibrosis: A systematic review and meta-analysis. Redox Biol 2020;32:101436. [PMID: 32044291 DOI: 10.1016/j.redox.2020.101436] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 8.5] [Reference Citation Analysis]
15 Njoroge SW, Laposata M, Katrangi W, Seegmiller AC. DHA and EPA reverse cystic fibrosis-related FA abnormalities by suppressing FA desaturase expression and activity. J Lipid Res. 2012;53:257-265. [PMID: 22095831 DOI: 10.1194/jlr.m018101] [Cited by in Crossref: 45] [Cited by in F6Publishing: 18] [Article Influence: 4.1] [Reference Citation Analysis]
16 Katrangi W, Lawrenz J, Seegmiller AC, Laposata M. Interactions of linoleic and alpha-linolenic acids in the development of fatty acid alterations in cystic fibrosis. Lipids. 2013;48:333-342. [PMID: 23440519 DOI: 10.1007/s11745-013-3768-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
17 Pynn CJ, Henderson NG, Clark H, Koster G, Bernhard W, Postle AD. Specificity and rate of human and mouse liver and plasma phosphatidylcholine synthesis analyzed in vivo. J Lipid Res 2011;52:399-407. [PMID: 21068006 DOI: 10.1194/jlr.D011916] [Cited by in Crossref: 93] [Cited by in F6Publishing: 43] [Article Influence: 7.8] [Reference Citation Analysis]
18 Moukarzel S, Dyer RA, Innis SM. Complex Relation Between Diet and Phospholipid Fatty Acids in Children With Cystic Fibrosis. J Pediatr Gastroenterol Nutr 2017;64:598-604. [PMID: 28333826 DOI: 10.1097/MPG.0000000000001356] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
19 Strandvik B. Nutrition in Cystic Fibrosis—Some Notes on the Fat Recommendations. Nutrients 2022;14:853. [DOI: 10.3390/nu14040853] [Reference Citation Analysis]
20 Stallings VA, Schall JI, Maqbool A, Mascarenhas MR, Alshaikh BN, Dougherty KA, Hommel K, Ryan J, Elci OU, Shaw WA. Effect of Oral Lipid Matrix Supplement on Fat Absorption in Cystic Fibrosis: A Randomized Placebo-Controlled Trial. J Pediatr Gastroenterol Nutr 2016;63:676-80. [PMID: 27050056 DOI: 10.1097/MPG.0000000000001213] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
21 Vandebrouck C, Ferreira T. Glued in lipids: Lipointoxication in cystic fibrosis. EBioMedicine 2020;61:103038. [PMID: 33038767 DOI: 10.1016/j.ebiom.2020.103038] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
22 O'Connor MG, Seegmiller A. The effects of ivacaftor on CF fatty acid metabolism: An analysis from the GOAL study. J Cyst Fibros 2017;16:132-8. [PMID: 27473897 DOI: 10.1016/j.jcf.2016.07.006] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
23 Risé P, Volpi S, Colombo C, Padoan RF, D'orazio C, Ghezzi S, Melotti P, Bennato V, Agostoni C, Assael BM, Galli C. Whole blood fatty acid analysis with micromethod in cystic fibrosis and pulmonary disease. Journal of Cystic Fibrosis 2010;9:228-33. [DOI: 10.1016/j.jcf.2010.03.002] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
24 Njoroge SW, Laposata M, Boyd KL, Seegmiller AC. Polyunsaturated fatty acid supplementation reverses cystic fibrosis-related fatty acid abnormalities in CFTR−/− mice by suppressing fatty acid desaturases. The Journal of Nutritional Biochemistry 2015;26:36-43. [DOI: 10.1016/j.jnutbio.2014.09.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
25 Maqbool A, Stallings VA. Update on fat-soluble vitamins in cystic fibrosis. Current Opinion in Pulmonary Medicine 2008;14:574-81. [DOI: 10.1097/mcp.0b013e3283136787] [Cited by in Crossref: 42] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
26 Worgall TS. Lipid metabolism in cystic fibrosis. Current Opinion in Clinical Nutrition & Metabolic Care 2009;12:105-9. [DOI: 10.1097/mco.0b013e32832595b7] [Cited by in Crossref: 34] [Cited by in F6Publishing: 19] [Article Influence: 2.6] [Reference Citation Analysis]